| Literature DB >> 18234108 |
Manuel Etienne1, Pascal Chavanet, Louis Sibert, Frédéric Michel, Hervé Levesque, Bernard Lorcerie, Jean Doucet, Pierre Pfitzenmeyer, François Caron.
Abstract
BACKGROUND: There is currently a lack of consensus for the diagnosis, investigations and treatments of acute bacterial prostatitis (AP).Entities:
Mesh:
Substances:
Year: 2008 PMID: 18234108 PMCID: PMC2254416 DOI: 10.1186/1471-2334-8-12
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Mode of contamination and medical history of 371 patients with acute prostatitis
| n = 371 | N = 178 | n = 115 | n = 48 | n = 30 | |
| Community-acquired | 293 (79%) | 140 (79%) | 91 (79%) | 41 (86%) | 21 (71%) |
| Nosocomial | 78 (21%) | 37 (21%) | 24 (21%) | 7 (14%) | 9 (29%) |
| Hospital acquisition | 58 (75%) | 26 (69%) | 18 (75%) | 5 (72%) | 8 (87%) |
| Outpatient with urinary catheter | 20 (25%) | 11(31%) | 6 (25%) | 2 (28%) | 1 (13%) |
| Age (years) | |||||
| Median | 61 | 57 | 60 | 66 | 84 |
| Range | 18–99 | 19–96 | 18–88 | 22–99 | 69–96 |
| Number of co-morbidities | |||||
| ≤ 1 | 345 (93%) | 175 (98%) | 113 (98%) | 33 (69%) | 23 (78%) |
| ≥ 2 | 26 (7%) | 3 (2%) | 2 (2%) | 15 (31%) | 7 (22%) |
| Urological background | |||||
| Past history of UTI | 137 (37%) | 53 (30%) | 58 (50%) | 21 (43%) | 6 (19%) |
| Urinary drainage before admission | 42 (11%) | 23 (13%) | 12 (10%) | 4 (8%) | 2 (7%) |
| Past history of anatomical urological disorder | 45 (12%) | 25 (14%) | 14 (12%) | 4 (8%) | 7 (23%) |
| Past history of neurological bladder | 60 (16%) | 18 (10%) | 15 (13%) | 14 (30%) | 12 (40%) |
Figure 1Distribution of 371 patients with acute prostatitis (AP) according to their age and to the mode of contamination.
Causes of admission and clinical symptoms during the course of the disease of 371 patients with acute prostatitis (AP).
| n = 371 | n = 178 | n = 115 | n = 48 | n = 30 | |
| Fever | 297 (80%) | 142 (80%) | 97 (84%) | 37 (78%) | 19 (63%) |
| Urinary symptoms | |||||
| Functional symptoms | 266 (72%) | 153 (86%) | 69 (60%) | 27 (57%) | 15 (50%) |
| Bladder outlet obstruction | 61 (23%) | 52 (29%) | 9 (8%) | 12 (25%) | 6 (20%) |
| Cognitive disorder | 14 (4%) | 0 (0%) | 5 (4%) | 4 (8%) | 10((33%) |
| Miscellaneous symptoms | 28 (8%) | 0 (0%) | 2 (2%) | 21 (44%) | 7 (23%) |
| Fever | 297 (80%) | 154 (84%) | 86 (80%) | 38 (78%) | 19 (63%) |
| Chills | 135 (35%) | 47 (25%) | 60 (56%) | 14 (28%) | 7 (23%) |
| Urinary symptoms | 266 (72%) | 158 (86%) | 65 (60%) | 28 (57%) | 15 (50%) |
| - burning micturition | 143 (54%) | 79 (50%) | 36 (55%) | 23 (82%) | 5 (33%) |
| - pollakiuria | 200 (52%) | 77 (49%) | 35 (54%) | 18 (64%) | 9 (60%) |
| - dysuria | 79 (30%) | 53 (34%) | 15 (23%) | 7 (25%) | 4 (27%) |
| - bladder outlet obstruction | 61 (23%) | 46 (29%) | 5 (8%) | 7 (25%) | 3 (20%) |
| - macroscopic haematuria | 46 (17%) | 33 (21%) | 9 (14%) | 2 (7%) | 2 (13%) |
| Pelvic pain | 144 (43%) | 98 (58%) | 27 (28%) | 18 (42%) | 1 (4%) |
| Abnormal digital rectal examination | 235 (83%) | 135 (89%) | 55 (70%) | 25 (83%) | 20 (91%) |
| - painful prostate palpation | 175 (63%) | 115 (77%) | 31 (39%) | 15 (50%) | 14 (64%) |
| - prostatic hypertrophy | 152 (54%) | 86 (57%) | 36 (46%) | 16 (53%) | 14 (63%) |
| - prostate irregularity | 66 (24%) | 44 (30%) | 10 (13%) | 4 (13%) | 8 (22%) |
Bacteriological results of urine cultures versus mode of contamination in a series of 371 acute prostatitis (AP)
| n = 371 | n = 295 | n = 76 | ||
| 347 (94%) | 271 (92%) | 76 (100%) | 0.02 | |
| Sterile | 122 (35%) | 96 (35%) | 29 (38%) | 0.71 |
| Positive | 225 (65%) | 178 (66%) | 47 (62%) | 0.71 |
| One strain | 196 (87%) | 159 (89%) | 37 (79%) | 0.09 |
| ≥ 2 strains | 29 (13%) | 19 (11%) | 10 (21%) | 0.09 |
| 270 | 213 (79%) | 57 (21%) | < 0.001 | |
| | ||||
| All types | 157 (58%) | 142 (68%) | 15 (26%) | < 0.01 |
| Ampicillin-S | 95 (61%) | 88 (62%) | 7 (50%) | 0.4 |
| Nalidixic acid-S | 119 (76%) | 110 (78%) | 9 (57%) | 0.2 |
| Ofloxacin-S | 130 (83%) | 120 (85%) | 10 (64%) | 0.2 |
| Cotrimoxazole-S | 122 (78%) | 115 (81%) | 7 (43%) | < 0.01 |
| | 16 (6%) | 11 (5%) | 5 (9%) | 0.5 |
| | 24 (9%) | 18 (8%) | 6 (11%) | 0.8 |
| | 16 (6%) | 8 (4%) | 8 (14%) | 0.02 |
| | 20 (7%) | 8 (4%) | 12 (21%) | < 0.01 |
| | 8 (3%) | 3 (1%) | 5 (9%) | 0.02 |
| | 29 (11%) | 23 (11%) | 6 (11%) | 0.9 |
Percentage of patients undergoing biological, imaging and functional investigations versus admission department
| 163 (44%) | 69 (39%) | 52 (45%) | 27 (55%) | 15 (50%) | |
| 286 (77%) | 128 (72%) | 105 (91%) | 32 (67%) | 22 (73%) | |
| 78 (21%) | 37 (21%) | 16 (14%) | 7 (15%) | 18 (59%) | |
| 122 (33%) | 77 (43%) | 9 (8%) | 0 (0%) | 0 (0%) | |
| 152 (41%) | 85 (48%) | 15 (13%) | 3 (6%) | 3 (11%) | |
*Other investigations: abdomen X-ray, intravenous urography, retrograde cystography, uro-CT-scan, and cystoscopy.
Antibiotic treatment and rates of microbiological and clinical failure versus mode of contamination and department in a series of 371 acute prostatitis (AP).
| Community acquired Versus nosocomial AP | ||||||||
| n = 371 | n = 293 | n = 78 | p value | n = 178 | n = 115 | n = 48 | n = 30 | |
| | ||||||||
| Bi-therapy | 215 (58%) | 172 (59%) | 43 (55%) | 0.7 | 123 (69%) | 63 (55%) | 20 (42%) | 9 (30%) |
| Use of fluoroquinolone | 234 (63%) | 187 (64%) | 47 (60%) | 0.7 | 148 (83%) | 47 (41%) | 20 (42%) | 19 (63%) |
| Use of 3rd generation cephalosporin | 113 (30%) | 85 (29%) | 28 (36%) | 0.3 | 25 (14%) | 59 (51%) | 22 (46%) | 7 (23%) |
| Use of amino glycosides | 195 (52%) | 165 (56%) | 30 (38%) | 0.007 | 120 (67%) | 60 (52%) | 14 (29%) | 1 (3%) |
| Use of other classes | 44 (12%) | 28 (10%) | 16 (21%) | 0.01 | 8 (4%) | 12 (10%) | 12 (25%) | 12 (40%) |
| | 42/269 (16%) | 17/210 (8%) | 25/59 (42%) | <0.001 | 27/137 (20%) | 4/76 (5%) | 6/31 (19%) | 5/25 (25%) |
| Bi-therapy | 15 (4%) | 13 (4%) | 2(3%) | 0.7 | 3 (2%) | 11 (10%) | 0 (0%) | 1 (3%) |
| Use of fluoroquinolone | 285 (77%) | 242 (82%) | 43 (55%) | <0.001 | 148 (83%) | 85 (74%) | 31 (65%) | 21 (70%) |
| Use of 3rd generation cephalosporin | 18 (5%) | 11 (4%) | 7 (9%) | 0.1 | 9 (5%) | 1 (1%) | 5 (10%) | 3 (10%) |
| Use of cotrimoxazole | 52 (14%) | 44 (15%) | 8 (10%) | <0.001 | 13 (7%) | 33 (29%) | 5 (10%) | 1 (3%) |
| Use of other classes | 31 (8%) | 9 (3%) | 22 (28%) | <0.001 | 11 (6%) | 7 (6%) | 7 (15%) | 6 (20%) |
| | 18/269 (7%) | 11/210 (5%) | 7/59 (12%) | 0.1 | 14/137 (10%) | 1/76 (1%) | 1/31 (3%) | 2/25 (8%) |
| 32 | 34 | 29 | 0.13 | 22 | 49 | 33 | 33 | |
| 37/153 (24%) | 23/124 (19%) | 14/29 (48%) | 0.002 | 16/76 (21%) | 2/32 (6%) | 1/6 (16%) | 4/9 (44%) | |
| - same strain | 7 | 3 | 4 | 8 | 0 | 0 | 0 | |
| - other strain | 30 | 20 | 10 | 8 | 2 | 1 | 4 | |
| 137/183 (75%) | 98/135 (73%) | 39/48 (83%) | 0.3 | 88/123 (71%) | 28/36 (78%) | 8/10 (80%) | 13/14 (92%) | |
* The adequacy of the treatment was studied for the 169 patients with a positive urine culture and an antibiotic-resistance pattern of the pathogenic strain.
Risk factors for clinical and bacteriological failure
| Age | < 0.001 | < 0.001 | 1.040 |
| history of prostate hyperplasia | 0.024 | NS** | ND† |
| neurological bladder | 0.033 | NS** | ND† |
| number of co-morbidities | 0.004 | NS** | ND† |
| urinary symptoms | 0.013 | NS** | ND† |
| haematuria | 0.005 | 0.012 | 0.320 |
| painful digital rectal examination | 0.014 | 0.017 | 0.340 |
| discovery of prostate hyperplasia | 0.005 | NS** | ND† |
| other anatomical or functional pathology | < 0.001 | 0.013 | 4.720 |
| Anti inflammatory treatment | 0.003 | 0.003 | 0.350 |
| Age | 0.001 | 0.002 | 1.060 |
| history of urinary catheter | 0.001 | 0.010 | 4.612 |
| neurological bladder | 0.002 | NS** | ND† |
| number of co-morbidities | 0.044 | NS** | ND† |
| pollakiuria | 0.006 | NS** | ND† |
| Dysuria | 0.047 | NS** | ND† |
| bladder outlet obstruction | 0.004 | NS** | ND† |
| | 0.006 | 0.013 | 7.279 |
| infection with 2 or more strains | 0.001 | 0.008 | 5.329 |
| prostate nodular lesion on ultrasound | 0.005 | NS** | ND† |
| post void residual urine on ultrasound | 0.001 | NS** | ND† |
| other anatomical or functional pathology | 0.004 | NS** | ND† |
| inadequate probabilistic antibiotic treatment | < 0.001 | 0.002 | 4.570 |
| urinary drainage with Foley catheter | 0.002 | NS** | ND† |
| urinary drainage with supra pubic catheter | 0.039 | NS** | ND† |
*Clinical failure: patient reporting persistent clinical symptoms at the follow-up visit.
** NS: Not Significant, †ND: Not Determined
††Bacteriological failure: positive urine culture at the follow-up visit.